about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

On a roll, Dicer­na notch­es $100M up­front as Eli Lil­ly eyes RNAi ap­pli­ca­tions in neu­rode­gen­er­a­tion, pain

7 years ago
Pharma

Long­time Api­tope CEO Kei­th Mar­tin steps down; Clear­side Bio­med­ical taps Spark ex­ec as CMO

7 years ago
Peer Review

Carv­ing a pipeline out of trou­bled Te­va, Or­biMed leads $60M launch of new NASH play­er

7 years ago
Financing
Startups

Hong Kong IPO de­liv­ers $421M to In­novent as an­oth­er one of Chi­na's biotech uni­corns hauls in big mon­ey

7 years ago
Financing
China

UCB, Bio­gen ad­mit de­feat in PhII lu­pus tri­al, adding to a string of late-stage fail­ures in the field

7 years ago
R&D

In key en­dorse­ment, Deer­field re­serves $65M for drug ven­ture with UNC-Chapel Hill

7 years ago
Financing

Fi­deli­ty, Val­or pool $71.8M for Jeff Aron­in's plan to re­for­mu­late a gener­ic for but­ter­fly skin dis­ease at Cas­tle ...

7 years ago
Financing

Medi­vir taps ex-Aca­dia chief Uli Hack­sell as in­ter­im CEO; Mer­ck on­boards chief dig­i­tal of­fi­cer

7 years ago
Peer Review

Take­da gets Japan­ese an­titrust reg­u­la­tors' bless­ing for Shire deal; France's Ac­ti­cor Biotech rais­es €15.3M for ...

7 years ago
News Briefing

Eiger chalks up one win, one loss be­tween a pair of PhII rare dis­ease drugs, reshuf­fling pri­or­i­ties

7 years ago
R&D

Genen­tech builds new of­fice in Ore­gon af­ter trim­ming HQ staff; Re­searchers laud ke­t­a­mine as a re­place­ment for opi­oids

7 years ago
News Briefing

Re­gen­eron, Sanofi talk up po­ten­tial block­buster fran­chise as Dupix­ent sweeps in rhi­nos­i­nusi­tis PhI­II

7 years ago
R&D

Tai­ho antes up an ex­tra $250M for its ven­ture arm as it gets se­ri­ous about 'glob­al on­col­o­gy' deals

7 years ago
Financing

In­novent to seek $400M-plus on Hong Kong IPO, re­ports say; will it re­vive biotech's for­tunes on HKEX?

7 years ago
Financing
China

Seek­ing cash to fund PhI­II for once-failed drug, Ad­ynxx rides Alli­qua's shell to Nas­daq

7 years ago
Deals

Per­ri­go taps ex-to­bac­co ex­ec as new CEO; Dana Far­ber T cell in­ves­ti­ga­tor Nick Hain­ing joins Mer­ck

7 years ago
Peer Review

Ab­b­Vie staves off an­oth­er US Hu­mi­ra knock­off to 2023 as Eu­ro­pean launch looms

7 years ago
Pharma

Te­va-part­nered Cell­tri­on biosim­i­lar scores FDA ad­comm rec­om­men­da­tion for a sec­ond shot at shak­ing up Roche's Rit­ux­an ...

7 years ago
Pharma

CRISPR Ther­a­peu­tics, Ver­tex set for first sick­le cell dis­ease tri­al af­ter FDA lifts clin­i­cal hold — just don't look ...

7 years ago
Pharma

Drop in clin­i­cal tri­al num­bers un­der­scores drug­mak­er­s' fears over Brex­it that trace back over a year

7 years ago
R&D
Pharma

Check­point ther­a­pies be­fore surgery? MD An­der­son team re­ports en­cour­ag­ing ef­fi­ca­cy but wor­ries about tox­i­c­i­ty

7 years ago
R&D

As CRISPR emerges, re­searchers spot­light pos­i­tive ef­fects in pre­na­tal gene edit­ing treat­ment for mice

7 years ago
Discovery

No­var­tis bets PRV on its next big mul­ti­ple scle­ro­sis drug — eyes US, EU ap­provals in '19

7 years ago
Pharma

Bel­gian up­start Rewind taps Ian Reynolds as CEO; Robert Fos­ter takes the reins at Con­traVir

7 years ago
Peer Review
First page Previous page 109110111112113114115 Next page Last page
A service from the Financial Times